Nurix Therapeutics, Inc.

Pharmaceutical Preparations

NRIX Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001549595 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$2.60B
103,781,683 shares Covers every share class this company has on file.
Insiders on file
2
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$4.19M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
0.16%
insider-held value divided by market capitalisation

What Nurix Therapeutics, Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$83.98M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$264.46M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
317
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Nurix Therapeutics, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

People who file insider reports against Nurix Therapeutics, Inc..
Insider Reported role Shares Value Last action
Gwenn Hansen Other Executive 115,005 $3.01M S Open-market sale Sep 1, 2026 position reported
Hans van Houte CFO 45,427 $1.19M S Open-market sale Aug 4, 2026 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Hans van Houte sold 20,000 Nurix Therapeutics, Inc. (NRIX) shares for $504,400 on Aug 26, 2024

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Hans van Houte sold 20,000 Nurix Therapeutics, Inc. (NRIX) shares for $504,400 on Aug 26, 2024
Date Insider Transaction Shares Price Value Filing
Aug 26, 2024 Hans van Houte S Open-market sale 20,000 held after: 31,002 $25.22 $504,400 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 111 rows we hold, 0 are open-market purchases and 44 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Nurix Therapeutics, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Sep 1, 2026 Gwenn Hansen S Open-market sale 1,452 $25.47 $37.0K SEC filing ↗
Sep 1, 2026 Gwenn Hansen M Option exercise or conversion 1,452 $1.86 $2.7K SEC filing ↗
Aug 5, 2026 Gwenn Hansen S Open-market sale 4,356 $25.00 $108.9K SEC filing ↗
Aug 5, 2026 Gwenn Hansen M Option exercise or conversion 4,356 $1.86 $8.1K SEC filing ↗
Aug 4, 2026 Gwenn Hansen S Open-market sale 2,611 $24.64 $64.3K SEC filing ↗
Aug 4, 2026 Gwenn Hansen S Open-market sale 1,500 $23.87 $35.8K SEC filing ↗
Aug 4, 2026 Hans van Houte S Open-market sale 2,967 $24.65 $73.1K SEC filing ↗
Aug 4, 2026 Hans van Houte S Open-market sale 1,794 $23.89 $42.9K SEC filing ↗
Jul 30, 2026 Hans van Houte S Open-market sale 2,845 $23.38 $66.5K SEC filing ↗
Jul 30, 2026 Hans van Houte M Option exercise or conversion 3,572 $0.00 $0 SEC filing ↗
Jul 30, 2026 Hans van Houte M Option exercise or conversion 2,858 $0.00 $0 SEC filing ↗
Jul 30, 2026 Hans van Houte M Option exercise or conversion 3,750 $0.00 $0 SEC filing ↗
Jul 30, 2026 Gwenn Hansen S Open-market sale 3,847 $23.38 $89.9K SEC filing ↗
Jul 30, 2026 Gwenn Hansen M Option exercise or conversion 3,572 $0.00 $0 SEC filing ↗
Jul 30, 2026 Gwenn Hansen M Option exercise or conversion 2,858 $0.00 $0 SEC filing ↗
Jul 30, 2026 Gwenn Hansen M Option exercise or conversion 3,750 $0.00 $0 SEC filing ↗
Jun 25, 2026 Gwenn Hansen S Open-market sale 5,394 $20.00 $107.9K SEC filing ↗
May 5, 2026 Hans van Houte S Open-market sale 582 $17.18 $10.0K SEC filing ↗
May 5, 2026 Hans van Houte S Open-market sale 13,473 $16.58 $223.4K SEC filing ↗
Apr 30, 2026 Hans van Houte S Open-market sale 2,388 $16.65 $39.8K SEC filing ↗
Apr 30, 2026 Hans van Houte M Option exercise or conversion 2,858 $0.00 $0 SEC filing ↗
Apr 30, 2026 Hans van Houte M Option exercise or conversion 3,750 $0.00 $0 SEC filing ↗
Apr 30, 2026 Hans van Houte M Option exercise or conversion 2,000 $0.00 $0 SEC filing ↗
Apr 30, 2026 Gwenn Hansen S Open-market sale 3,214 $16.65 $53.5K SEC filing ↗
Apr 30, 2026 Gwenn Hansen M Option exercise or conversion 2,858 $0.00 $0 SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Nurix Therapeutics, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Nurix Therapeutics, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.